By Fineline Cube 
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase III study for its cyclosporine A eye gel, a treatment candidate for moderate to severe dry eye disease. This marks a significant milestone in the development of this novel therapy, which aims to improve patient outcomes and convenience.
Product Differentiation and Advantages
Zhaoke’s cyclosporine A eye gel is formulated with proprietary hydrogels, distinguishing it from AbbVie’s Restasis, which uses an emulsion formula. This innovative approach enhances the pharmacokinetics and ocular surface exposure of the drug. A previous Phase II clinical study demonstrated that the cyclosporine A eye gel (0.05%, once daily) is comparable in efficacy and safety to Restasis (0.05% cyclosporine A, twice daily). The once-nightly dosing regimen further improves medication adherence for patients.
Clinical Development and Patient Impact
The initiation of the Phase III study is a critical step toward potential commercialization and broad availability of this new dry eye treatment. By addressing the limitations of existing therapies, Zhaoke’s cyclosporine A eye gel has the potential to become a preferred option for patients managing moderate to severe dry eye disease.-Fineline Info & Tech